US20020136708A1
(en)
*
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
EP0787200B1
(en)
|
1994-10-28 |
2005-04-20 |
The Trustees Of The University Of Pennsylvania |
Improved adenovirus and methods of use thereof
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6924128B2
(en)
*
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
US5843742A
(en)
*
|
1994-12-16 |
1998-12-01 |
Avigen Incorporated |
Adeno-associated derived vector systems for gene delivery and integration into target cells
|
US5652224A
(en)
*
|
1995-02-24 |
1997-07-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6187757B1
(en)
*
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
DE69638058D1
(de)
*
|
1995-06-15 |
2009-11-26 |
Crucell Holland Bv |
Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
|
FR2737222B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
US6207457B1
(en)
|
1995-09-08 |
2001-03-27 |
Avigen, Inc. |
Targeted nucleotide sequence delivery and integration system
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US6541012B2
(en)
|
1996-06-24 |
2003-04-01 |
Christoph Bogedain |
System for the production of AAV vectors
|
EP0931158A1
(en)
*
|
1996-09-06 |
1999-07-28 |
The Trustees Of The University Of Pennsylvania |
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
|
IL131979A0
(en)
*
|
1997-03-21 |
2001-03-19 |
Enzo Therapeutics Inc |
Vectors and viral vectors and packaging cell lines for propagating the same
|
US8703480B1
(en)
|
1997-03-21 |
2014-04-22 |
Enzo Therapeutics, Inc. |
Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
|
IT1291135B1
(it)
*
|
1997-04-08 |
1998-12-29 |
Angeletti P Ist Richerche Bio |
Vettori ricombinanti utilizzabili in terapia genica
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6054312A
(en)
*
|
1997-08-29 |
2000-04-25 |
Selective Genetics, Inc. |
Receptor-mediated gene delivery using bacteriophage vectors
|
US6989264B2
(en)
*
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
EP1015619A1
(en)
|
1997-09-19 |
2000-07-05 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
GB9721909D0
(en)
*
|
1997-10-17 |
1997-12-17 |
Cantab Pharma Res |
Gene delivery vectors and their uses
|
US6346415B1
(en)
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
JP2001526900A
(ja)
*
|
1997-12-23 |
2001-12-25 |
イントロヘーネ ベスローテン フェンノートシャップ |
標的細胞の染色体dnaへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス
|
JP2002505085A
(ja)
*
|
1998-02-17 |
2002-02-19 |
ジェンザイム・コーポレイション |
精製aavベクターの生産方法
|
US6953690B1
(en)
*
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
US20060183228A1
(en)
*
|
1998-03-24 |
2006-08-17 |
Enzo Therapeutics, Inc. |
Viral vectors with surface or envelope components
|
GB9813670D0
(en)
*
|
1998-04-08 |
1998-08-26 |
Angeletti P Ist Richerche Bio |
Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
|
US6521426B1
(en)
*
|
1998-04-08 |
2003-02-18 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
|
US6413776B1
(en)
*
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
EP1092035B1
(en)
|
1998-07-01 |
2006-03-01 |
Institut für Virologie Teilrechtsfähiges Institut an der Veterinärmedizinischen Universität Wien |
Targeted integration into chromosomes using retroviral vectors
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
GB9817660D0
(en)
*
|
1998-08-13 |
1998-10-07 |
Angeletti P Ist Richerche Bio |
Adenoviral vectors encoding erythropoietin and their use in gene therapy
|
ATE294874T1
(de)
|
1998-09-11 |
2005-05-15 |
Univ California |
Rekombinante adenovirus für gewebespezifische genexpression ins herz
|
US6395549B1
(en)
|
1998-10-22 |
2002-05-28 |
Medical College Of Georgia Research Institute, Inc. |
Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
US6303362B1
(en)
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US6387368B1
(en)
*
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US20040043488A1
(en)
*
|
1999-02-17 |
2004-03-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Adeno-associated viral gene-transfer vector system
|
EP1815848A1
(en)
*
|
1999-02-22 |
2007-08-08 |
Georgetown University |
Antibody fragment-targeted immunoliposomes for systemic gene delivery
|
US6258595B1
(en)
*
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6893865B1
(en)
*
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
PT1818408E
(pt)
*
|
1999-05-17 |
2011-11-15 |
Crucell Holland Bv |
Adenovírus recombinante do serótipo ad11
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6793926B1
(en)
*
|
1999-05-27 |
2004-09-21 |
Genovo, Inc. |
Methods for production of a recombinant adeno-associated virus
|
US7094398B1
(en)
*
|
1999-06-01 |
2006-08-22 |
University Of Washington |
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
|
WO2000073478A2
(en)
*
|
1999-06-01 |
2000-12-07 |
University Of Washington |
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
|
CA2385538C
(en)
*
|
1999-09-17 |
2007-11-06 |
Tgt Laboratories, S.A. De C.V. |
Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars
|
WO2001025253A2
(en)
|
1999-10-01 |
2001-04-12 |
The University Of North Carolina At Chapel Hill |
Temperature-sensitive regulation of viral vector production
|
US7115391B1
(en)
*
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
AU7841400A
(en)
*
|
1999-10-01 |
2001-05-10 |
Genovo, Incorporated |
Production of recombinant aav using adenovirus comprising aav rep/cap genes
|
CA2387484A1
(en)
*
|
1999-10-12 |
2001-04-19 |
Haim Burstein |
Adeno-associated virus vectors encoding factor viii and methods of using the same
|
RU2164944C1
(ru)
*
|
1999-12-09 |
2001-04-10 |
Институт молекулярной биологии им. В.А. Энгельгардта РАН |
Способ изменения генетических свойств организма
|
US6965010B2
(en)
*
|
2000-02-25 |
2005-11-15 |
Licentia, Ltd. |
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
|
WO2001083796A2
(en)
*
|
2000-05-03 |
2001-11-08 |
University Of Washington |
Adenoviral vectors for tumor specific gene expression and uses thereof
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
WO2002024730A2
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
CA2422524A1
(en)
*
|
2000-09-25 |
2002-03-28 |
Motoyuki Yamashita |
Pei: dna vector formulations for in vitro and in vivo gene delivery
|
DE60138403D1
(de)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
MXPA00011713A
(es)
*
|
2000-11-28 |
2002-05-31 |
Tgt Lab S A De C V |
Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
US20060275262A1
(en)
*
|
2001-07-26 |
2006-12-07 |
Mathis James M |
Conditionally replicating viruses and methods for cancer virotherapy
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
CA2460157A1
(en)
|
2001-09-18 |
2003-03-27 |
Clontech Laboratories, Inc. |
Site-specific recombinase based method for producing adenoviral vectors
|
NZ532635A
(en)
|
2001-11-13 |
2007-05-31 |
Univ Pennsylvania |
A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
|
AU2002365366B2
(en)
|
2001-11-21 |
2007-05-10 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
EP1944043A1
(en)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
CA2469053C
(en)
*
|
2001-12-17 |
2011-08-23 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
|
EP1453547B1
(en)
|
2001-12-17 |
2016-09-21 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
|
CA2369985A1
(en)
*
|
2002-01-18 |
2003-07-18 |
Duke University |
Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
ATE447037T1
(de)
*
|
2002-04-25 |
2009-11-15 |
Crucell Holland Bv |
Mittel und verfahren zur herstellung von adenovirusvektoren
|
WO2003092594A2
(en)
|
2002-04-30 |
2003-11-13 |
Duke University |
Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
|
WO2004050680A2
(en)
*
|
2002-05-08 |
2004-06-17 |
Intronn, Inc. |
Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
WO2004038380A2
(en)
*
|
2002-10-23 |
2004-05-06 |
Intronn, Inc. |
Screening methods for identification of efficient pre-trans-splicing molecules
|
DE60331367D1
(de)
|
2002-12-30 |
2010-04-01 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
EP1587923B1
(en)
|
2003-01-22 |
2011-08-24 |
Duke University |
Improved constructs for expressing lysosomal polypeptides
|
JP2006522022A
(ja)
|
2003-02-14 |
2006-09-28 |
ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ |
プロテアソーム干渉に関連する避妊法および組成物
|
US20070037284A1
(en)
*
|
2003-06-04 |
2007-02-15 |
Enzo Therapeutics, Inc. |
Vectors for expressing exogenous gene or exogenous nucleic acid sequences
|
US7491508B2
(en)
*
|
2003-06-20 |
2009-02-17 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US7291498B2
(en)
*
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US20050120398A1
(en)
*
|
2003-09-12 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Animal model for HCV infection
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
WO2005070948A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
AU2005207053A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Virxsys Corporation |
Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
|
WO2005078848A2
(en)
*
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
EP1732947B1
(en)
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
US7319015B2
(en)
*
|
2004-03-16 |
2008-01-15 |
The Regents Of The University Of Michigan |
Methods and compositions for using alveolar macrophage phospholipase A2
|
US7582442B2
(en)
|
2004-03-16 |
2009-09-01 |
The Regents Of The University Of Michigan |
Methods and compositions for using aleveolar macrophage phospholipase A2
|
EP1742668B1
(en)
*
|
2004-04-28 |
2011-02-09 |
The Trustees of The University of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
ES2442225T3
(es)
*
|
2004-04-28 |
2014-02-10 |
The Trustees Of The University Of Pennsylvania |
Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
|
ES2292271B1
(es)
*
|
2004-05-20 |
2009-02-16 |
Proyecto De Biomedicina Cima, S.L. |
Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
|
EP1755400A2
(en)
*
|
2004-06-18 |
2007-02-28 |
The University Of Montana |
Aav mediated gene delivery to cochlear cells
|
WO2006014798A2
(en)
*
|
2004-07-27 |
2006-02-09 |
Mount Sinai School Of Medicine |
Methods and compositions for using sax2
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
FI20050753A
(fi)
|
2004-09-03 |
2006-03-04 |
Licentia Oy |
Uudet peptidit
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
US7879321B2
(en)
*
|
2004-10-08 |
2011-02-01 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
CN101124328A
(zh)
*
|
2004-12-15 |
2008-02-13 |
北卡罗来纳查佩尔山大学 |
嵌合载体
|
US7531523B2
(en)
*
|
2005-02-17 |
2009-05-12 |
Vertex Pharmaceuticals Incorporated |
Sodium channel protein type III alpha-subunit splice variant
|
SG163572A1
(en)
*
|
2005-07-11 |
2010-08-30 |
Globeimmune Inc |
Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
|
ES2363758T3
(es)
|
2005-08-15 |
2011-08-16 |
Vegenics Pty Ltd |
Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
|
US7972813B2
(en)
*
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
ES2352205T3
(es)
|
2005-12-14 |
2011-02-16 |
Licentia Ltd. |
Usos de una proteína del factor neurotrófico.
|
US20090214496A1
(en)
*
|
2006-01-30 |
2009-08-27 |
Licentia Ltd. |
Bmx/etk tyrosine kinase gene therapy materials and methods
|
AR053600A1
(es)
|
2006-04-28 |
2007-05-09 |
Fundacion Inst Leloir |
Un fragmento aislado de adn del promotor humano de a33 y su uso para dirigir la expresion de un gen heterologo en celulas tumorales
|
US8114399B2
(en)
|
2006-05-17 |
2012-02-14 |
Ludwig Institute For Cancer Research |
Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
|
WO2008011344A2
(en)
*
|
2006-07-17 |
2008-01-24 |
Nationwide Children's Hospital Inc. |
Disruption of programmed death-1 (pd-1) ligands to adjuvant adeno-associated virus vector vaccines
|
KR100808269B1
(ko)
|
2006-07-18 |
2008-02-29 |
연세대학교 산학협력단 |
Cag 프로모터를 포함하는 아데노바이러스용 재조합 셔틀벡터
|
WO2008067480A2
(en)
|
2006-11-29 |
2008-06-05 |
Nationwide Children's Hospital |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
WO2008091276A2
(en)
*
|
2007-01-25 |
2008-07-31 |
Amprotein Corporation |
Use of chick beta actin gene intron-1
|
WO2008115610A1
(en)
*
|
2007-03-19 |
2008-09-25 |
Globeimmune, Inc. |
Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
FI20070808A0
(fi)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
GDNF:n silmukointivariantit ja niiden käytöt
|
JP5758124B2
(ja)
|
2007-11-28 |
2015-08-05 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルサブファミリーCアデノウイルスSAdV−40、−31および−34ならびにそれらの用途
|
CA2964396A1
(en)
|
2007-11-28 |
2009-06-11 |
The Trustees Of The University Of Pennsylvania |
Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
|
US20090196854A1
(en)
*
|
2008-02-04 |
2009-08-06 |
Kytos Biosystems S.A. |
Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
|
EP2250255A2
(en)
|
2008-03-04 |
2010-11-17 |
The Trustees of the University of Pennsylvania |
Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
EP2318036B1
(en)
|
2008-06-30 |
2015-06-03 |
The Regents of the University of Michigan |
Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
|
JP5809978B2
(ja)
|
2008-10-31 |
2015-11-11 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスSAdV−43、−45、−46、−47、−48、−49および−50ならびにそれらの用途
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
EP2412387B1
(en)
|
2009-03-27 |
2014-11-19 |
Proyecto de Biomedicina Cima, S.L. |
Methods and compositions for the treatment of cirrhosis and liver fibrosis
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
CA2762203A1
(en)
|
2009-05-29 |
2010-12-02 |
Soumitra Roy |
Simian adenovirus 41 and uses thereof
|
TWI480363B
(zh)
*
|
2009-08-19 |
2015-04-11 |
Jnc Corp |
四氫吡喃化合物、液晶組成物及液晶顯示元件
|
CN102712933A
(zh)
|
2009-11-05 |
2012-10-03 |
西马生物医学计划公司 |
调控的表达系统
|
DK2539015T3
(da)
|
2010-02-26 |
2016-04-04 |
Univ Cornell |
Nethindeprotese
|
CA2833908C
(en)
|
2010-04-23 |
2021-02-09 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
MX2013002375A
(es)
|
2010-08-31 |
2013-10-07 |
Univ Cornell |
Protesis de retina.
|
US9302103B1
(en)
|
2010-09-10 |
2016-04-05 |
Cornell University |
Neurological prosthesis
|
CN103492016A
(zh)
|
2010-11-23 |
2014-01-01 |
普莱萨格生命科学公司 |
用于实体递送的治疗方法和组合物
|
EP3075860A1
(en)
|
2010-11-23 |
2016-10-05 |
The Trustees of the University of Pennsylvania |
Subfamily e simian adenovirus a1295 and uses thereof
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
ES2702496T3
(es)
|
2011-04-21 |
2019-03-01 |
Nationwide Childrens Hospital Inc |
Productos de virus recombinante y procedimientos para la inhibición de la expresión de la miotilina
|
EP2710037B1
(en)
|
2011-05-19 |
2019-07-31 |
The Regents of The University of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
WO2013016352A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
WO2013026015A1
(en)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Muc1 ligand traps for use in treating cancers
|
EP2748765B1
(en)
|
2011-08-25 |
2022-12-14 |
Cornell University |
Retinal encoder for machine vision
|
WO2013078316A1
(en)
|
2011-11-23 |
2013-05-30 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
ES2784194T3
(es)
|
2011-11-30 |
2020-09-23 |
Ludwig Inst For Cancer Res Ltd |
Moduladores de células iNKT y métodos para uso el mismo
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
SG11201407343XA
(en)
|
2012-05-18 |
2014-12-30 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
CA2880653C
(en)
|
2012-08-01 |
2022-05-17 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
EP2892617B1
(en)
|
2012-09-06 |
2018-06-13 |
The University of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
JP2015529685A
(ja)
|
2012-09-17 |
2015-10-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute Atnationwide Children’S Hospital |
筋萎縮性側索硬化症の処置のための組成物および方法
|
JP2016500254A
(ja)
*
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
代謝疾患の調節のための方法および組成物
|
WO2014124487A1
(en)
|
2013-02-18 |
2014-08-21 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
AU2014253730B2
(en)
|
2013-04-20 |
2018-09-13 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus delivery of exon 2-targeted U7snRNA polynucleotide constructs
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
EP4219727A3
(en)
|
2013-08-27 |
2023-09-06 |
Research Institute at Nationwide Children's Hospital |
Products and methods for treatment of amyotrophic lateral sclerosis
|
EP3065784A4
(en)
|
2013-11-05 |
2017-05-10 |
The Research Institute at Nationwide Children's Hospital |
COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
|
WO2015070009A2
(en)
|
2013-11-08 |
2015-05-14 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
JP6908381B2
(ja)
|
2014-01-29 |
2021-07-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Muc1−c/細胞外ドメイン(muc1−c/ecd)に対する抗体
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
DK3116900T3
(da)
|
2014-03-09 |
2020-09-28 |
Univ Pennsylvania |
Sammensætninger som kan anvendes til behandling af ornithintranscarbamylase (otc) defekt
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP3572516A1
(en)
|
2014-08-09 |
2019-11-27 |
The Research Institute at Nationwide Children's Hospital |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
WO2016057975A2
(en)
|
2014-10-10 |
2016-04-14 |
Research Institute At Nationwide Children's Hospital |
Guided injections for aav gene transfer to muscle
|
RU2738421C2
(ru)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
WO2016073693A2
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
CA2966884A1
(en)
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
AU2015346162B2
(en)
|
2014-11-14 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP6863891B2
(ja)
|
2014-11-14 |
2021-04-21 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
調節性ポリヌクレオチド
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
CN107532168A
(zh)
|
2015-02-23 |
2018-01-02 |
克里斯珀医疗股份公司 |
治疗血红蛋白病的材料和方法
|
ES2846902T3
(es)
|
2015-04-08 |
2021-07-30 |
Univ Chicago |
Composiciones y procedimientos para corregir la distrofia muscular de cinturas tipo 2C mediante omisión de exones
|
WO2016172188A1
(en)
|
2015-04-20 |
2016-10-27 |
Cornell University |
Machine vision with dimensional data reduction
|
CA3019315A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
JP7338970B2
(ja)
|
2015-09-17 |
2023-09-05 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Galgt2遺伝子治療のための方法および物質
|
WO2017064546A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
EP3368063B1
(en)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materials and methods for treatment of duchenne muscular dystrophy
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
JP6987068B2
(ja)
|
2015-11-09 |
2021-12-22 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
癌マーカーおよび治療標的としてのグリピカン2
|
IL259441B2
(en)
|
2015-11-16 |
2024-01-01 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for the treatment of titin-based myopathies and other titinopathy
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
JP6947729B2
(ja)
|
2015-12-23 |
2021-10-13 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
筋萎縮性側索硬化症及び/または前頭側頭葉変性症の治療のための材料及び方法
|
WO2017120589A1
(en)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
EP3420109A4
(en)
|
2016-02-26 |
2019-11-06 |
Research Institute at Nationwide Children's Hospital |
RECOMBINANT VIRUS PRODUCTS AND METHOD OF INDUCING DUX4 EXON SKIPPING
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
BR112018070249A2
(pt)
|
2016-04-02 |
2019-01-29 |
Research Institute At Nationwide Children's Hospital |
sistema promotor de u6 modificada para expressão específica de tecido
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
IL262262B2
(en)
|
2016-04-15 |
2023-10-01 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of B-sarcoglycan and microRNA-29 and treatment of muscular dystrophy
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
MX2018012729A
(es)
|
2016-04-18 |
2019-07-04 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de hemoglobinopatias.
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EP3458589A4
(en)
|
2016-05-18 |
2020-01-01 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
AU2017290614C1
(en)
|
2016-06-29 |
2024-01-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
EP3478313B1
(en)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
EP3478829A1
(en)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
AU2017362491B2
(en)
|
2016-11-17 |
2023-02-02 |
Nationwide Children's Hospital Inc. |
Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
|
EP3555296A4
(en)
|
2016-12-13 |
2020-07-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN MODIFIED CELLS IN VITRO AND IN VIVO
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
EP3585898A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
US11338045B2
(en)
|
2017-03-17 |
2022-05-24 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
BR112019019248A2
(pt)
|
2017-03-17 |
2020-04-28 |
Research Institute At Nationwide Children's Hospital |
entrega de vetor de vírus adeno-associado de microdistrofina específica muscular para tratamento de distrofia muscular
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
AU2018367896B2
(en)
|
2017-05-12 |
2023-06-01 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2019011817A1
(en)
|
2017-07-08 |
2019-01-17 |
Genethon |
TREATMENT OF SPINAL AMYOTROPHY
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavを送達するための組成物および方法
|
AU2018338188A1
(en)
|
2017-09-22 |
2020-04-02 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
CA3077426A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
US11534501B2
(en)
|
2017-10-18 |
2022-12-27 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
US11926653B2
(en)
|
2017-10-20 |
2024-03-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for NT-3 gene therapy
|
MA50849A
(fr)
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
CA3082136A1
(en)
|
2017-11-08 |
2019-05-16 |
Avexis, Inc. |
Means and method for preparing viral vectors and uses of same
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
CA3084633A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
MA51637A
(fr)
|
2018-01-12 |
2020-11-18 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage de la transferrine
|
EP3749767A1
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
AU2019239957A1
(en)
|
2018-03-19 |
2020-09-10 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and uses thereof
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
US20210255185A1
(en)
|
2018-06-08 |
2021-08-19 |
Novartis Ag |
Cell-based assay for measuring drug product potency
|
GB201809588D0
(en)
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
US20210301305A1
(en)
|
2018-06-13 |
2021-09-30 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (utr) for aav production
|
AU2019288291A1
(en)
|
2018-06-18 |
2021-01-21 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
|
CA3103485A1
(en)
|
2018-06-18 |
2019-12-26 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
BR112020026853A2
(pt)
|
2018-06-29 |
2021-04-20 |
Research Institute At Nationwide Children's Hospital |
produtos de vírus adeno-associados recombinantes e métodos para tratar a distrofia muscular de cinturas tipo 2a
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
CA3110665A1
(en)
|
2018-08-29 |
2020-03-05 |
Research Institute At Nationwide Children's Hospital |
Products and methods for inhibition of expression of mutant gars protein
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
EP3861107A1
(en)
|
2018-10-05 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
JP7384457B2
(ja)
*
|
2018-10-09 |
2023-11-21 |
ナイキジェン,リミテッド |
ウイルスベクターを調製するための組成物および方法
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
US20210348159A1
(en)
|
2018-10-17 |
2021-11-11 |
Crispr Therapeutics Ag |
Compositions and methods for delivering transgenes
|
TW202039859A
(zh)
|
2018-11-30 |
2020-11-01 |
美商艾夫西斯公司 |
Aav病毒載體及其用途
|
CA3122319A1
(en)
|
2018-12-21 |
2020-06-25 |
Genethon |
Expression cassettes for gene therapy vectors
|
AU2019419494A1
(en)
|
2018-12-31 |
2021-07-15 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
CA3128230A1
(en)
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
EA202192160A1
(ru)
|
2019-02-04 |
2021-11-17 |
Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал |
Доставка полинуклеотида cln3 с помощью аденоассоциированного вируса
|
MX2021009404A
(es)
|
2019-02-04 |
2021-11-12 |
Res Inst Nationwide Childrens Hospital |
Administracion del virus adenoasociado de polinucleotido de cln6.
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
EP3930765A1
(en)
|
2019-02-26 |
2022-01-05 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
MA55297A
(fr)
|
2019-03-12 |
2022-01-19 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
|
US20220193259A1
(en)
|
2019-04-15 |
2022-06-23 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
EP3966327A1
(en)
|
2019-05-08 |
2022-03-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
AU2020278960A1
(en)
|
2019-05-17 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
US20200407729A1
(en)
|
2019-06-28 |
2020-12-31 |
Crispr Therapeutics Ag |
Materials and methods for controlling gene editing
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
AU2020319168B2
(en)
|
2019-07-25 |
2024-02-29 |
Novartis Ag |
Regulatable expression systems
|
MX2022002132A
(es)
|
2019-08-21 |
2022-05-18 |
Res Inst Nationwide Childrens Hospital |
Administracion de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular.
|
US20220378945A1
(en)
|
2019-10-18 |
2022-12-01 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
JP2022552014A
(ja)
|
2019-10-18 |
2022-12-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Irf2bpl遺伝子の変異に関連する障害の治療のための材料および方法
|
AU2020385387A1
(en)
|
2019-11-22 |
2022-06-02 |
Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico |
Materials and methods for treatment of disorders associated with the IGHMBP2 gene
|
CN115516100A
(zh)
|
2019-12-20 |
2022-12-23 |
全国儿童医院研究所 |
靶向肌肉疾病中肌肉的优化基因疗法
|
EP4107266A1
(en)
|
2020-02-18 |
2022-12-28 |
Research Institute at Nationwide Children's Hospital |
Aav-mediated targeting of mirna in the treatment of x-linked disorders
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
WO2021209521A1
(en)
|
2020-04-14 |
2021-10-21 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
CA3187353A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
EP4214317A2
(en)
|
2020-09-15 |
2023-07-26 |
Research Institute at Nationwide Children's Hospital |
Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
|
AU2021349277A1
(en)
|
2020-09-28 |
2023-05-11 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
WO2022115745A1
(en)
|
2020-11-30 |
2022-06-02 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
US20220228142A1
(en)
|
2020-12-17 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
WO2022164860A1
(en)
|
2021-01-27 |
2022-08-04 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
US20240093191A1
(en)
|
2021-02-03 |
2024-03-21 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating disease associated with dux4 overexpression
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
JP2024508324A
(ja)
|
2021-03-04 |
2024-02-26 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dmdエクソンの重複を修正するためのcrispr-cas9を使用したジストロフィンベースのミオパチーの治療のための生成物及び方法
|
EP4305157A1
(en)
|
2021-03-09 |
2024-01-17 |
Huidagene Therapeutics (Singapore) Pte. Ltd. |
Engineered crispr/cas13 system and uses thereof
|
CA3216711A1
(en)
|
2021-04-13 |
2022-10-20 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
|
WO2022226334A1
(en)
|
2021-04-23 |
2022-10-27 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
EP4334447A1
(en)
|
2021-05-07 |
2024-03-13 |
UCL Business Ltd |
Abca4 genome editing
|
BR112023024078A2
(pt)
|
2021-05-17 |
2024-01-30 |
Sarepta Therapeutics Inc |
Produção de vetores de aav recombinantes para o tratamento de distrofia muscular
|
EP4108263A3
(en)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
CA3222950A1
(en)
|
2021-06-11 |
2022-12-15 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
CA3225084A1
(en)
|
2021-07-14 |
2023-01-19 |
MEIRAGTX, UK II Limited |
Retgc gene therapy
|
IL310018A
(en)
|
2021-07-14 |
2024-03-01 |
Meiragtx Uk Ii Ltd |
KCNV2 gene therapy
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
IL310725A
(en)
|
2021-08-11 |
2024-04-01 |
Solid Biosciences Inc |
Treatment of muscular dystrophy
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
WO2023060215A1
(en)
|
2021-10-07 |
2023-04-13 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
WO2023060233A1
(en)
|
2021-10-08 |
2023-04-13 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
US20230139985A1
(en)
|
2021-10-15 |
2023-05-04 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
US20230279431A1
(en)
|
2021-11-30 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
EP4198048A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3 gene transfer increase using modified itr sequences
|
EP4198134A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Gamma-sarcoglycan gene transfer increase using modified itr sequences
|
EP4198047A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Fukutin related protein gene transfer increase using modified itr sequences
|
EP4198046A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Alpha-sarcoglycan gene transfer increase using modified itr sequences
|
WO2023122669A1
(en)
|
2021-12-21 |
2023-06-29 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023168400A2
(en)
|
2022-03-03 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024064913A1
(en)
|
2022-09-23 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Recombinant aav vectors for treating muscular dystrophy
|